💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Brigatinib

CHEMBL3545311 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
584.1 g/mol
LogP
4.6
Phase
4

A next-generation ALK inhibitor used to treat non-small cell lung cancer in patients whose tumors have an ALK gene rearrangement, particularly those who have progressed on other ALK inhibitors. It is designed to overcome resistance mechanisms and penetrate the brain, where lung cancer frequently spreads. It is taken orally once daily.

Khối lượng phân tử

584,1000 g/mol

LogP

4,60

TPSA

85,90 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer

Cơ chế tác dụng

Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1

                

                

                
                

                    
InChI

                    
InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)

                

                

                

                    
                    

                        
Molecular Formula

                        
C29H39ClN7O2P

                    

                    
                    

                        
HBD / HBA

                        
2 / 9

                    

                    
                    

                        
Liên kết có thể quay

                        
8

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
40

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
A next-generation ALK inhibitor used to treat non-small cell lung cancer in patients whose tumors have an ALK gene rearrangement, particularly those who have progressed on other ALK inhibitors. It is designed to overcome resistance mechanisms and penetrate the brain, where lung cancer frequently spreads. It is taken orally once daily.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Brigatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3545311.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 68165256.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.